Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype.
about
Mechanisms of Vascular Calcification: The Pivotal Role of Pyruvate Dehydrogenase Kinase 4VKORC1L1, an enzyme rescuing the vitamin K 2,3-epoxide reductase activity in some extrahepatic tissues during anticoagulation therapyDephosphorylated-uncarboxylated Matrix Gla protein concentration is predictive of vitamin K status and is correlated with vascular calcification in a cohort of hemodialysis patients.A review of the effect of diet on cardiovascular calcification.Differential Effects of Dabigatran and Warfarin on Bone Volume and Structure in Rats with Normal Renal FunctionMechanisms of arterial remodeling: lessons from genetic diseases.Warfarin accelerates ectopic mineralization in Abcc6(-/-) mice: clinical relevance to pseudoxanthoma elasticumCharacterization of vitamin K-dependent carboxylase mutations that cause bleeding and nonbleeding disorders.Intake of dietary phylloquinone and menaquinones and risk of stroke.Inflammatory, metabolic, and genetic mechanisms of vascular calcification.Two cases of warfarin-induced tracheobronchial calcification after Fontan surgery.The realm of vitamin K dependent proteins: shifting from coagulation toward calcification.Direct oral anticoagulants: an alternative treatment for thrombotic antiphospholipid syndrome?Of nanobacteria, nanoparticles, biofilms and their role in health and disease: facts, fancy and future.Rationale and design of a randomized trial of apixaban vs warfarin to evaluate atherosclerotic calcification and vulnerable plaque progression.Vitamin K and cancer.Annexin A5 reduces early plaque formation in ApoE -/- mice.Effects on bone metabolism markers and arterial stiffness by switching to rivaroxaban from warfarin in patients with atrial fibrillation.Impact of age on cerebrovascular dilation versus reactivity to hypercapnia.Ucma/GRP inhibits phosphate-induced vascular smooth muscle cell calcification via SMAD-dependent BMP signalling.Vitamin K antagonist use and renal function in pre-dialysis patients.Oral Anticoagulation in Chronic Kidney Disease and Atrial Fibrillation.Is Matrix Gla Protein Associated with Vascular Calcification? A Systematic Review.Effects of menaquinone-7 supplementation in patients with aortic valve calcification: study protocol for a randomised controlled trialMissense mutation of VKORC1 leads to medial arterial calcification in rats
P2860
Q26753184-DBED7255-BB3D-4DFE-963E-E8FD079E1C98Q28114887-61407971-A29E-47A4-8C36-8D3B81F5168CQ34241519-41AB44FE-2A36-428B-97B6-CEF03EE4304AQ35585755-723A4799-E7C0-4E38-830C-0137B08D4F70Q35737441-F0D2B04F-AD3F-44DE-81F3-A32F170D68F2Q36463642-DE51CA7B-92B8-45D5-8A64-2896DDD705D9Q36750182-EB1D632D-05A9-45EF-9C4A-91F6AEA9D679Q36800446-2CB0C921-6777-415D-9046-5790EDDFE67DQ37457640-059F5899-6705-4113-A8DA-D2A0C1AD2D77Q37683430-493110BA-526F-413B-857A-628831B04B52Q38192464-7CEBAAD5-2E4E-4C86-BA5D-83D3A8F23C19Q38199459-FBF3BB72-B52C-4111-BE71-40E99EBF2CACQ38868618-40CE6F90-60C9-474E-931F-BEBFF74339CAQ39200253-984AB69D-AEE1-4DF0-8383-F9B4F5371285Q45937484-D7787CA7-B19C-4AFD-9446-BF3AE0CD3FA0Q47249966-0E4251E8-2501-4DE6-9F6F-37DE765D4393Q47350152-4AE39F3D-A213-4D12-8960-B757E1582F86Q48199806-D5511992-F9B3-44DC-AAA6-E760BB26A7F9Q48987635-DF7B1A9A-4284-4FE3-9E5A-FB4AEEBA9F19Q52643921-615F4942-1DCF-4EFC-87D2-03215E53105EQ54940282-711034BF-9F9B-4DC6-B6F7-121236C28B5EQ55001247-99C295DE-5214-4AE5-BD68-E4B505D0D12AQ55283688-E6F21CE6-2C08-4DF4-A01D-7AA9C2B77729Q58713157-3E71F846-BA08-41C6-B95D-96EF88044E01Q58743826-C44B4C22-27C5-48A8-9B56-741C64AC9603
P2860
Vitamin K-antagonists accelerate atherosclerotic calcification and induce a vulnerable plaque phenotype.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Vitamin K-antagonists accelera ...... a vulnerable plaque phenotype.
@ast
Vitamin K-antagonists accelera ...... a vulnerable plaque phenotype.
@en
Vitamin K-antagonists accelera ...... a vulnerable plaque phenotype.
@nl
type
label
Vitamin K-antagonists accelera ...... a vulnerable plaque phenotype.
@ast
Vitamin K-antagonists accelera ...... a vulnerable plaque phenotype.
@en
Vitamin K-antagonists accelera ...... a vulnerable plaque phenotype.
@nl
prefLabel
Vitamin K-antagonists accelera ...... a vulnerable plaque phenotype.
@ast
Vitamin K-antagonists accelera ...... a vulnerable plaque phenotype.
@en
Vitamin K-antagonists accelera ...... a vulnerable plaque phenotype.
@nl
P2093
P2860
P50
P1433
P1476
Vitamin K-antagonists accelera ...... a vulnerable plaque phenotype.
@en
P2093
Chris P Reutelingsperger
Eduard M Laufer
Erik Biessen
Ivo A Joosen
Leon J Schurgers
Leonard Hofstra
Marjolein Herfs
Mark H M Winkens
Martijn L L Chatrou
Ralf Westenfeld
P2860
P304
P356
10.1371/JOURNAL.PONE.0043229
P407
P577
2012-08-29T00:00:00Z